Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome

with No hi ha comentaris
  • Oriol-Tordera, B., Esteve-Codina, A., Berdasco, M., Rosás-Umbert, M., Gonçalves, E., Duran-Castells, C., Clotet, B., Martínez-Picado, J., Paredes, R., Calle, M. L., Mothe, B., Brander, C., . . . Ruiz-Riol, M. (2022). Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. EBioMedicine, 78.
    https://doi.org/10.1016/j.ebiom.2022.103956

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *